Selank

What Selank does

Selank is a synthetic peptide used as a nasal anxiety medicine in Russia. Most small studies lacked placebo comparisons; lasting benefit and safety remain unclear. Some reports may reuse participants. Injected use has not been established.

• In Russia, its nose drops are given to people for anxiety and stress-related symptoms; this is not an approved use in the US. (Studied in a trial)
• In a small trial against a sedative anxiety drug, it caused less drowsiness, though anxiety scores fell a bit less. (Studied in a trial)
• In a small study (15 vs 15 people) of adjustment problems, those taking it had lower symptom scores at day 28. (Studied in a trial)
• People report calm focus and better productivity, often alongside Semax, though some notice no effect. (Reported by users)

Uses in the sources

• Studied for generalized anxiety, neurasthenia and other anxiety disorders. Evidence is short-term and mostly from Russia. (Studied in a trial) (source)
• Russian nasal instructions include anxiety, stress-related symptoms and adjustment problems. (Clinician-published) (source)
• People report calm focus, better productivity or no effect, often with Semax. (Reported by users) (source)

Selank dosage

Typical reported dose: Two drops in each nostril, three times a day

• Early study: one test dose: 900 mcg intranasally once single test dose, nasal spray. Studied in a trial. Studied in: Adults with psychogenic anxiety. (source)
• Anxiety study: 2700 mcg/day: 2700 mcg/day intranasally daily total; within-day split not stated, nasal spray. Studied in a trial. Studied in: Adults with generalized anxiety disorder. (source)
• Older-adult pilot: three daily doses: 2700 mcg/day as 900 mcg three times daily daily total in three equal administrations, nasal spray. Studied in a trial. Studied in: Adults over 50 with vascular cognitive symptoms. (source)
• Anxiety comparison: 2.7 mg/day: 2700 mcg/day for 14 days daily total; within-day split not specified, nasal spray. Studied in a trial. Studied in: Adults with anxiety-spectrum disorders. (source)
• Selank added to phenazepam: 2700 mcg/day on days 1–14 with phenazepam, then Days 15–21: 20/40 continued; the other 20 stopped daily total; within-day split not specified, nasal spray. Studied in a trial. Studied in: Adults with anxiety-spectrum disorders. (source)
• Parkinson/tremor pilot: three weeks: 1350 mcg/day intranasally daily total; within-day split not stated, nasal spray. Studied in a trial. Studied in: Adults with Parkinson disease or essential tremor. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Selank

Comes as: Community-reported freeze-dried powder vials, labelled 5 or 10 mg, Home-mixed nasal sprays.

Mixed with: Community reply: nasal saline, 10 mL for a 10 mg vial. No verified human injection-mixing protocol was found..

Common vial sizes: 5, 10 mg. Common water amounts: 10 mL.

• A poster assumed 0.1 mL per spray. Actual pump output was not measured, so this is not a verified delivered dose.
• A shared bottle or combined solution has no verified compatibility or microbial-safety data.
• Russian finished nasal drops need no mixing; their historical storage instructions are recorded with those clinical-practice protocols.

Before mixing: No validated storage conditions or shelf life were found for unregulated powder vials. Finished-medicine instructions do not establish powder stability.

After mixing: No validated after-mixing shelf life was found. A saline recipe does not establish stability, preservation or microbial quality.

Selank side effects and risks

Reported side effects

• Unpleasant taste: Russian instructions describe taste when nasal solution reaches the throat; no rate given., mild (source)
• Allergic reaction: Possible with intolerance; no frequency estimate in Russian instructions., serious (source)
• Longer sleep: 13% Selank versus 93% phenazepam on day 14 in a 60 person open trial., mild (source)
• Memory problems: 10% Selank versus 83% phenazepam on day 14 in the same trial., moderate (source)
• Concentration problems: 7% Selank versus 97% phenazepam on day 14., moderate (source)
• Weakness or fatigue: 3% Selank versus 77% phenazepam on day 14., mild (source)
• Nasal dryness: 7% Selank versus 0% phenazepam on day 21, one week after treatment stopped., mild (source)

Stop and get help if

• Trouble breathing, face or throat swelling, or collapse: Stop exposure and get emergency care now.
• Sudden weakness, facial droop, speech trouble or sudden vision loss: Call emergency services immediately; do not delay stroke care for a peptide.

Who should avoid it

• pregnant: Russian instructions contraindicate pregnancy; controlled pregnancy safety studies are absent.
• breastfeeding: Russian instructions contraindicate breastfeeding; infant exposure and safety are unknown.
• tryingToConceive: Precaution: reproductive safety and a preconception washout interval are not established.
• under18: Russian pediatric use does not establish safety of online preparations.
• other: Avoid after allergy to the peptide or formulation, including its preservatives.
• testedAthlete: 2026 status is unresolved for the exact substance and formulation; obtain an anti-doping ruling.
• kidneyDisease: No reliable dose-adjustment studies for kidney impairment were located.
• liverDisease: No reliable dose-adjustment studies for liver impairment were located.
• psychiatricCondition: Review symptoms and psychiatric medicines; the available trials do not cover every diagnosis or combination.
• other: Blocked or irritated nasal passages can make delivery unreliable; review persistent nose symptoms.
• autoimmuneDisease: Immune-marker changes were reported; effects in autoimmune disease are unstudied. This is a precaution.
• immunosuppressed: Immune effects and interactions with immune-suppressing care are unknown. This is a precaution.
• seizureDisorder: Safety in seizure disorders is not established; review neurological history and medicines.

Interactions

• Benzodiazepines and other sedating substances: A small phenazepam study does not establish safety with other sedatives. Sedation still occurred with the combination.
• Antidepressants and antipsychotics: One small escitalopram study and laboratory data do not establish safety across these drugs.
• Semax and modified nootropic peptides: The combination is reported online; the brain-imaging study tested separate drug groups.

Product quality risks

• Seized powders were identified as Semax and Selank by mass spectrometry; that study did not establish sterility or a market-wide contamination rate.
• FDA flags immune reactions from aggregation and peptide-related impurities. A nasal route does not remove quality risks.
• Unregulated preparations can contain the wrong amount, microbes or bacterial toxins. No representative assay survey of these two products was found.

What to expect

A human anxiety study used Selank for 14 days while measuring immune markers; this does not establish a long-term treatment course.

20 human reports may include repeated participants. People often knew which treatment they received; lasting benefit and safety remain unclear.

Key studies

• Generalized anxiety and neurasthenia: A small active-comparator trial does not prove equivalence. (source)
• Immune markers during anxiety care: Blood-marker changes do not show protection from infections. (source)
• Selank versus phenazepam: Less sedation, but a smaller day-14 anxiety-score reduction. (source)
• Adding Selank to phenazepam: The day-14 responder comparison was not statistically significant. (source)
• Early phase 2 congress report: A selected sample was studied in a conference report. (source)
• Rapid versus gradual response: Response groups were defined after treatment without a placebo control. (source)

Selank FAQ

• Is Selank FDA-approved? No. Nasal medicine registered in Russia; newer registry mirror checked. The dosing instruction retrieved is an older version.
• How do people take it? Nasal spray, three times daily. 14 days. Source: clinician-published.
• What's the difference between Selank and Semax? Selank: a Russian nasal anxiety peptide with uncertain long-term benefit and safety. Semax: a Russian nasal peptide with limited human evidence for brain and nerve effects. Why people pair them: people combine them for focus with less perceived anxiety. No human trial tested the combination.
• Can I take it with Semax? People combine them for focus with less perceived anxiety. No human trial tested the combination. Combined effects, compatibility and long-term safety are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? It is unclear (WADA 2026). S0 requires no approval by any government. Russian registration prevents an automatic S0 conclusion; obtain a substance-specific ruling.
• How long does a mixed vial last? No validated after-mixing shelf life was found. A saline recipe does not establish stability, preservation or microbial quality.